PureHelix™ Genomic Prep Kit [Plant] (Solution based)
- Known as:
- PureHelix™ Genomic Prep Kit [Plant] (Solution based)
- Catalog number:
- GSP400
- Product Quantity:
- 400 preps/kit
- Category:
- -
- Supplier:
- NanoHelix
- Gene target:
- PureHelix™ Genomic Prep Kit [Plant] (Solution based)
Related genes to: PureHelix™ Genomic Prep Kit [Plant] (Solution based)
- Gene:
- PREP NIH gene
- Name:
- prolyl endopeptidase
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 6q21
- Locus Type:
- gene with protein product
- Date approved:
- 1996-03-12
- Date modifiied:
- 2016-10-05
Related products to: PureHelix™ Genomic Prep Kit [Plant] (Solution based)
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(+)_1_(9_Fluorenyl)ethyl chloroformate 0.5 w_v% solution in ac(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: PureHelix™ Genomic Prep Kit [Plant] (Solution based)
- The development of an efficacious preventive human immunodeficiency virus (HIV) vaccine remains a central goal of global HIV elimination efforts, yet biological performance alone will not determine a future vaccine's public health impact. This review draws on behavioral science, communication research, vaccine implementation, and HIV prevention literature to identify cognitive, social, and structural challenges that are likely to shape public acceptance and uptake of a future HIV vaccine, as well as to outline evidence-based opportunities for addressing them. Based on the available literature, mental models of both HIV and vaccination will be a critical determinant of how communities consider a future vaccine, particularly given that emerging mRNA and adjuvanted platforms may generate side effects that could be easily misinterpreted and that highly effective long-acting pre-exposure prophylaxis (PrEP) options already exist and will shape how individuals evaluate a vaccine's relative value. HIV-related stigma further complicates this landscape by making vaccination a socially interpreted behavior, unlike some other vaccination efforts. Together, these factors suggest that hesitancy and misalignment between public understanding and scientific evidence are predictable and should be anticipated rather than addressed reactively. At the same time, decades of HIV prevention implementation research have established an evidence base for vaccine communication, and existing community engagement infrastructure offers a foundation upon which future rollout efforts can build. We highlight three evidence-based strategies as particularly promising levers for encouraging acceptance and adoption. We conclude with recommendations for HIV vaccine researchers and healthcare professionals to invest in formative research, build community partnerships in advance of vaccine availability, and pilot integrated delivery models within existing HIV prevention services. - Source: PubMed
Publication date: 2026/05/19
Bhushan Nivedita LGonzalez RafaelSouthwell Brian G - : Mpox vaccination is an important prevention strategy for men who have sex with men (MSM), yet responses to vaccination may not be adequately captured by a simple willing-versus-unwilling framing. We examined correlates of vaccination willingness and heterogeneity within the delayed/refused responses subgroup in Changsha, China. : A cross-sectional survey was conducted using respondent-driven sampling (RDS). Vaccination willingness was classified as immediate willingness versus delayed/refused responses. Analyses included cluster-robust logistic regression, RDS-weighted regression, generalized estimating equations, and a recruiter-linked network-lag model. Among respondents with delayed/refused responses, concern profiles were explored using unsupervised clustering of standardized concern items. : Among 405 recruited MSM without a self-reported mpox infection history, immediate willingness and delayed/refused responses were nearly equally distributed, indicating that lack of immediate willingness was common. Across primary models, ever use of pre-exposure prophylaxis (PrEP) and higher mpox-related information exposure frequency were the most consistent correlates of immediate willingness versus delayed/refused responses, whereas basic sociodemographic variables showed little evidence of independent association. Within the delayed/refused group, three partially overlapping patterns emerged: broadly elevated cross-domain concern, low-concern delay with few strongly endorsed barriers, and more selective safety- and burden-related concerns. These findings suggest that a lack of immediate willingness may arise through different psychosocial pathways rather than a single common mechanism. : Mpox vaccination willingness among MSM in Changsha appeared to be shaped more by prevention-related behaviors and psychosocial factors than by basic sociodemographic profiles alone. Vaccination strategies may benefit from cross-topic sexual-health communication, integrated prevention efforts, and subgroup-sensitive approaches to delayed or refused willingness. - Source: PubMed
Publication date: 2026/05/10
Zhou YingyingWang WenqiangKuang YunHu QiangShen LinXie QiangmingXie Zhi - : Although pre-exposure prophylaxis (PrEP) has demonstrated strong clinical efficacy in preventing HIV infection among men who have sex with men (MSM), real-world utilization remains suboptimal. In South Korea, MSM constitute a major population within the domestic HIV epidemic; however, PrEP uptake has not increased pro-portionally to awareness. This discrepancy has been conceptualized as the "awareness-uptake gap," reflecting multi-level barriers beyond individual knowledge. : This integrative review aimed to compare PrEP awareness, acceptance, and utilization among MSM populations in South Korea and international settings, and to identify structural, institutional, and psychosocial determinants contributing to the awaness, uptake gap. The study further sought to derive practical implications for nursing practice and health policy. : An integrative literature review was conducted following Whittemore and Knafl's five-step methodology and reported in line with PRISMA guidance. Electronic searches were performed in PubMed, Google Scholar, RISS, ScienceON, and DBpia for peer-reviewed studies published between 2015 and 2025 in English or Korean. The final search was completed on 31 January 2026. A total of 5952 records were identified, and 187 studies met the inclusion criteria after screening and duplicate removal. Quality appraisal was conducted using AXIS, Newcastle-Ottawa Scale, RoB 2.0, CASP, and MMAT according to study design, and the findings were synthesized within an environmental-structural-individual framework. : The included studies consistently showed that awareness of PrEP exceeded actual uptake. Across settings, the awareness-uptake gap was shaped by policy environment, service accessibility, stigma, privacy concerns, economic burden, institutional complexity, and provider preparedness. Comparative evidence from China, Thailand, Belgium and France, Brazil, and West Africa further suggested that awareness alone did not ensure uptake when service pathways were fragmented, culturally unsafe, or poorly understood. : Closing the awareness-uptake gap requires integrated policy and practice strategies that extend beyond cost reduction. Strengthening confidentiality systems, simplifying service pathways, and enhancing provider competency-particularly through nurse-centered PrEP navigation and counseling models-may support more sustainable PrEP expansion among MSM populations in global settings. - Source: PubMed
Publication date: 2026/04/22
Hwang Won JuKim HwiyunReynolds Nancy R - Sutab, a sodium sulfate oral tablet, was developed as an alternative to traditional colonoscopy preparation (prep) solutions, which usually involve the ingestion of about three liters of a polyethylene glycol (PEG) solution to clear the bowels. This traditional method can be unpleasant, leading to barriers for patients seeking colonoscopies due to the large volume of distasteful fluid and resulting diarrhea. Sutab consists of 24 sodium sulfate tablets; patients are instructed to take 12 tablets the night before the procedure with at least 16 ounces of water, followed by another 12 tablets 5-6 hours prior to the colonoscopy. Patients must also consume an additional 32 ounces of water for hydration during the prep. However, as Sutab is relatively new, ongoing research is needed. A few studies indicated potential side effects, including incidences of erosive gastritis and gastric ulcers in patients who used Sutab, raising concerns about its safety, particularly for populations with existing health issues. Here we present a case of a 53-year-old woman who used this method for colonoscopy prep and experienced complications, and aim to provide suggestions on how to mitigate these side effects. - Source: PubMed
Publication date: 2026/04/24
Machchhar RiddhiAlShobaki SaifAl Mahrizi Ahmed DMossolem FatimaGreenberg Alexandra - Italy has recently expanded access to oral pre-exposure prophylaxis (PrEP) and made rapid progress in long-acting PrEP (LA-PrEP) availability. These developments create a unique opportunity to assess population-level readiness for LA-PrEP and identify gaps that may limit its public health impact. - Source: PubMed
Publication date: 2026/05/25
Wang HaoyiKolstee JohannZimmermann Hanne M LTosh JonathanSchroeder MelanieJonas Kai J